FDA Panel Gives Partial Nod to RA Drug Baricitinib FDA Panel Gives Partial Nod to RA Drug Baricitinib

Agency officials will need to sort through the competing messages from their advisers as they weigh whether to allow a competitor to Pfizer ' s Janus kinase drug tofacitinib on the US market.Medscape Medical News

Source: Medscape Medical News Headlines - April 24, 2018 Category: Consumer Health News Tags: Rheumatology News Source Type: news